QIAGEN releases new CLC Genomics Workbench solution designed for use in significantly more customer segments
New solution incorporates the best of CLC Biomedical Genomics Workbench and CLC Genomics Workbench into a combined offering
GERMANTOWN, Maryland, and HILDEN, Germany, November 27, 2018 — QIAGEN today announced the release of a new bioinformatics analysis tool designed to bring the robustness and sophistication of the company’s industry-leading sequencing analysis solutions across research fields to biologists who do not have a primary focus on bioinformatics.
The new tool works with any species for any application and reinforces QIAGEN’s strategic push to expand the utility of its analysis tools well beyond the current core customer segment of bioinformaticians.
The new tool incorporates the best of two previous QIAGEN products — CLC Biomedical Genomics Workbench and CLC Genomics Workbench — bringing them together into one unified solution called CLC Genomics Workbench 12. As with earlier versions, the new product is ISO certified with full documentation and support.
Substantial improvements in this new product include:
- A streamlined, easy-to-use interface useful for scientists with any bioinformatics skill level
- A dramatically reduced data footprint (decreased by more than 50% compared to previous products) for use with compute resources available to virtually any lab
- An in-depth reference tool suite that allows users to get started quickly for many commonly studied species and genomic panels
- An array of plugins for specialized workflows
“This new analysis product, which we developed in response to customer feedback, will be useful to both advanced bioinformaticians as well as to researchers with other areas of focus,” said Frank Schacherer, VP Products and Solutions, QIAGEN Bioinformatics. “This new solution represents a meaningful improvement to the customer on every front: ease of use, compute requirements, broad applicability, robust references, and cost. We look forward to seeing the new scientific discoveries users will be able to make with this solution.”
CLC Genomics Workbench 12 is an important part of QIAGEN’s Sample to Insight pipeline, with functionality that makes it simple for users to analyze QIAseq Targeted DNA Panels and other NGS workflows. More than 10,000 scientists around the world rely on CLC Workbench tools for their genomic analysis needs.
“QIAGEN has made several strategic investments in the bioinformatics field in recent years, and the result of bringing those teams together has been a deeper understanding of the analysis needs not only within the advanced genomics community but also among the much larger biology research world,” said Jonathan Sheldon, Senior Vice President of QIAGEN’s Bioinformatics Business Area. “This launch represents an important step in our push to expand the impact of our portfolio of world-class bioinformatics tools to a bigger audience and enable better, faster science.”
Current users of Biomedical Genomics Workbench can choose to upgrade to this product – free of charge – and find the same specialized biomedical functionalities in addition to the many powerful tools that come with the CLC Genomics Workbench. Many improvements in the Graphical User Interface, speed of the resequencing pipelines, and >50% reduced data footprint make this choice highly attractive. Further information can be found at https://www.qiagenbioinformatics.com/products/clc-genomics-workbench.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2018, QIAGEN employed approximately 4,900 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).